Skip to content

Effects of oral fish oil on wound healing and inflammation in patients with diabetes foot ulcer: a randomized, double-blind, placebo-controlled study

Effects of oral fish oil on wound healing and inflammation in patients with diabetes foot ulcer: a randomized, double-blind, placebo-controlled study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073315
Enrollment
Unknown
Registered
2023-07-06
Start date
2022-11-03
Completion date
Unknown
Last updated
2023-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes foot uclers

Interventions

fish oil group:fish oil
Corn oil group:Corn oil

Sponsors

Second Affiliated Hospital of Army Medical University, PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) It meets the diagnostic criteria for diabetes proposed by WHO in 1999; (2) Age range: 18 to 70 years old; (3) Glycosylated hemoglobin HbA1c < 12%; (4) Wagner grading is between 1 and 3 levels; (5) At least one ulcer below the ankle, with a duration of at least one month and an area of = 1 cm2; (6) The ankle brachial index is 0.7 to 1.2; Or the back percutaneous oxygen test result is = 30 mmHg; Or the Doppler arterial waveform at the ankle is biphasic or better; (7) No treatment such as corticosteroids, antioxidants, or fish oil preparations has been received within the past three months; (8) Patients with a clear infection can be included in the study after infection control, i.e., after procalcitonin is reduced to normal.

Exclusion criteria

Exclusion criteria: (1) Allergies to any component in supplements; (2) Active Charcot neuroarthrosis; (3) Patients with malignant tumors or undergoing radiotherapy or chemotherapy due to tumors; (4) Known immunosuppressive diseases or receiving immunosuppressive treatment; (5) Collagen vascular disease or autoimmune disease; (6) Renal function impairment (blood urea nitrogen>21.4 mmol/l, creatinine>247.5 µ Mol/l), liver failure/cirrhosis (Child B or C), myocardial infarction; (7) In the past 2 weeks, they have received similar treatment such as bioengineered tissue or growth factors, or received treatment such as collagen or negative pressure suction that may affect the research results; (8) Pregnant or lactating women; (9) Patients with a history of mental illness who are unable to cooperate with this project study.

Design outcomes

Primary

MeasureTime frame
Proportion of subjects with a reduction in wound area = 50% within the 12th week;Proportion of subjects with complete ulcer healing at the 12th week (complete closure of the wound without drainage).;Percentage reduction in ulcer area at weeks 12 compared to week 0, with calculation of the mean for each group;Healing time: from the start of the study until wound healing or the end of observation.;

Secondary

MeasureTime frame
Serum inflammatory markers: IL-6, IL-8, TNF-a, hs-CRP;;Blood routine, neutrophil/lymphocyte ratio (NLR), and platelet/lymphocyte ratio (PLR);;Incidence of wound reinfection;

Countries

China

Contacts

Public ContactWang Jian

Second Affiliated Hospital of Army Medical University, PLA

wangjian_1996@aliyun.com+86 138 8329 7625

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026